正在加载图片...
[28 ASSIRI A, AL-TAWFIQ JA, AL-RABEEAH AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study[J]. Lancet Infect Dis, 2013, 13(9): 752-761 29 LEE N, HUI D, WU A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong]. N Engl J Med,2003,348(20):1986-1994 [30] ZHAO Y, ZHAO Z, WANG Y, et al. Single-cell RNA expression profiling of ACE2, the putative eceptorofwuhan2019-ncov[z].biorxIv,2020.https://doi.org/10.1101/2020.01.26.919985 [31 CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: A descriptive study[]. Lancet, 2020 B2] AL-TAWFIQ JA, GAUTRET P. Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV)infection: Extent and implications for infection control: A systematic review] Travel Med Infect Dis. 2019. 27: 27-3 33 STOCKMAN LJ, BELLAMY R, GARNER P SARS: Systematic review of treatment effects PLoS Med,2006,3(9):e343 34] LANSBURY LE, RODRIGO C, LEONARDI-BEE J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: An updated Cochrane systematic review and meta-analysis[J]. Crit Care med,2020,48(2):137-141 [35 ARABI YM, MANDOURAH Y, AL-HAMEED F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome[J]. Am J Respir Crit Care Med, 2018, 197(6):757-767 6] CHAN JF, CHAN KH, KAO RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus[]. J Infect, 2013, 67(6): 606-616 37] de WILDE AH, RAJ VS, OUDSHOORN D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment!JI J Gen virol,2013,94(Pt8):1749-1760 38]LU H. Drug treatment options for the 2019-new coronavirus(2019-nCoVJ]. Biosci Trends, 2020. 39]XU Z, PENG C, SHI Y, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and bindingfreeenergycalculation[z].Biorxiv,2020.https://doi.org/10.1101/2020.01.27.921627 编辑卓选鹏 数字平台:htp/ xxb xjtu.edu.cn微信公众号:西安交通大学学报医学版西安交通大学学报( 医学版 ) 数字平台:http://yxxb.xjtu.edu.cn 微信公众号:西安交通大学学报医学版 [28] ASSIRI A, AL-TAWFIQ JA, AL-RABEEAH AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study[J]. Lancet Infect Dis, 2013, 13(9):752-761. [29] LEE N, HUI D, WU A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong[J]. N Engl J Med, 2003, 348(20):1986-1994. [30] ZHAO Y, ZHAO Z, WANG Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV[Z]. biorxiv, 2020. https://doi.org/10.1101/2020.01.26.919985. [31] CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study[J]. Lancet, 2020. [32] AL-TAWFIQ JA, GAUTRET P. Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review[J]. Travel Med Infect Dis, 2019, 27:27-32. [33] STOCKMAN LJ, BELLAMY R, GARNER P. SARS: Systematic review of treatment effects[J]. PLoS Med, 2006, 3(9):e343. [34] LANSBURY LE, RODRIGO C, LEONARDI-BEE J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: An updated Cochrane systematic review and meta-analysis[J]. Crit Care Med, 2020, 48(2):137-141. [35] ARABI YM, MANDOURAH Y, AL-HAMEED F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome[J]. Am J Respir Crit Care Med, 2018, 197(6):757-767. [36] CHAN JF, CHAN KH, KAO RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus[J]. J Infect, 2013, 67(6):606-616. [37] de WILDE AH, RAJ VS, OUDSHOORN D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment[J]. J Gen Virol, 2013, 94(Pt 8):1749-1760. [38] LU H. Drug treatment options for the 2019-new coronavirus (2019-nCoV)[J]. Biosci Trends, 2020. [39] XU Z, PENG C, SHI Y, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation[Z]. Biorxiv, 2020. https://doi.org/10.1101/2020.01.27.921627. 编辑 卓选鹏
<<向上翻页
©2008-现在 cucdc.com 高等教育资讯网 版权所有